City: San Marino
Home City: San Marino
San Marino News - business, entertainment and technology news from San Marino, California
Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft...
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announces the results of the clinical trial entitled 'Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma' at the ASCO Annual Meeting on June 8, 2010. The presentation will be discussed by Dr. Kristen N. Ganjoo, Stanford University Medical Center, Palo Alto CA.
FDA Fast Track Designation for the Treatment of Pancreatic Cancer Given to Rexin-G®
SAN MARINO, Calif. /California Newswire/ -- Epeius Biotechnologies announced this week that its lead product, Rexin-G, has been granted Fast Track designation by the...
Rexin-G® Nano Particles Target Metastatic Cancers
SAN MARINO, Calif. /California Newswire/ -- Epeius Biotechnologies' Rexin-G is the world's smallest hero. Imagine if you will, a tiny particle that can travel...
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma
SAN MARINO, Calif. /California Newswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed...
Beginners Luck, or Creative Artists of the First Rank? Epeius Bio Launches Rexin-G eBook Tutorial
SAN MARINO, Calif. /California Newswire/ -- Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book...
Rexin-G® Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer
SAN MARINO, Calif. /California Newswire/ -- Epeius Biotechnologies (epeiusbiotech.com) announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of...
Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting...
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma
SAN MARINO, Calif. -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue...
Epeius Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in...
Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced the publication of another landmark paper describing recent technological advances in medical gene delivery. The...
Rexin-G for Metastatic Cancer Aptly Highlighted by National Cancer Institute Journal
SAN MARINO -- Epeius Biotechnologies Corporation today announced that Rexin-G®, its lead product in development for metastatic cancer, has been highlighted in a recent...
FDA Grants Rexin-G from Epeius Biotechnologies a Third Orphan Drug Designation
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Rexin-G(R) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration...
Epeius Biotechnologies’ Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for Osteosarcoma Treatment
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration...
IV Infusions of Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity
SAN MARINO, Calif. -- ASCO 2008 -- Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic...
Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes
SAN MARINO, Calif. -- Epeius Biotechnologies (www.epeiusbiotech.com) announced today that the results of a Phase I Feasibility Study of sequential targeted gene delivery-using Rexin-G...
Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
SAN MARINO, Calif. -- Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast...
ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity without Toxicity in Metastatic Pancreatic Cancer
SAN MARINO, Calif. -- Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic pancreatic cancer (Chawla et...
Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G's anti-tumor activity with no major toxicity in patients with metastatic chemotherapy-resistant pancreatic cancer. The clinical trial design includes 5 escalating doses of intravenous Rexin-G ranging from 1 x 10e11 cfu twice a week to 4 x 10e11 cfu three times a week for 4 weeks. Treatment cycles are repeated if the patient exhibits Grade 1 or less toxicity.
Epeius Bio Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today the issue of U.S. Patent No. 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company's leading anti-cancer agent, Rexin-G. As Targeted Gene Therapy Comes of Age in Clinical Medicine, Epeius Biotechnologies Applauds Their Academic Contemporaries
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definitive meeting entitled "In Vivo Barriers to Gene Delivery" was held at the prestigious Cold Spring Harbor Laboratory, where Nobel laureate James Watson presides, or shall we say presided.
ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that the company has received a Certificate of Product Registration for Rexin-G(R) from the Philippine Bureau of Food and Drugs (BFAD), enabling the commercialization of its lead product as a safe and effective treatment for a broad spectrum of intractable cancers.
FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G for Osteosarcoma
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that the company has taken a major step toward the commercialization of its lead product with the opening of a Phase II Registration Protocol using Rexin-G for osteosarcoma in the United States. Following the accelerated approval of Rexin-G for the treatment of all solid tumors by the Bureau of Food and Drugs in the Philippines, Epeius opened a number of Phase I/II clinical trials.
Epeius Biotechnologies Leads with Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference...
SAN MARINO, Calif. and BOSTON, Mass. -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies Inc., has accepted an invitation to give the lead keynote address on "The Advent of Pathotropic Medicine for Cancer" at the Global Pharma R&D Summit 2007 to be held in Boston MA.
California Biotech Company Takes Aim at Pancreatic Cancer With an Advanced Phase I/II Clinical Trial
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that an advanced Phase I/II clinical trial using intravenous Rexin-G(TM) for pancreatic cancer that is refractory to standard chemotherapy will open in the summer of 2007 in Los Angeles, California. Rexin-G is the world's first tumor-targeted injectable gene delivery system that is designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body.
Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced the publication of a historic landmark in medical oncology and a definitive benchmark in the emerging field of cancer gene therapy. The first clinical report of its kind, Le Morte du Tumour - was published in the June issue of the International Journal of Oncology. Epeius Biotechnologies Gains FDA Approval for Two New Clinical Trials Using Rexin-G(TM) for Breast Cancer and Sarcoma
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today the expansion of ongoing clinical trials using Rexin-G(TM) in the United States to include breast cancer and all types of sarcomas that have failed standard chemotherapy. Following on the heels of their landmark clinical trials in the United States and abroad, the US FDA granted Orphan Drug Status for Rexin-G.
Epeius Biotechnologies to Present the Advent of Tumor Targeting Technology at C21 BioVentures Conference
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak during the 9th annual C21 BioVentures Conference. On May 23 Dr. Hall will present the scientific principles, clinical validation, and global development status of the company's innovative tumor-targeting technology. Japanese Study Confirms Safety and Efficacy of Intravenous Rexin-G
SAN MARINO, Calif. -- Epeius Biotechnologies announced today the first results of an independent study conducted in Japan that further documents the safety and efficacy of intravenous Rexin-G in a broad spectrum of patients with chemo-resistant metastatic cancer. Although the study began in October, only two months ago, the initial reports are both encouraging and noteworthy. The lead investigator of the Japanese study, Dr. Takaki Imamura, will be presenting his findings and clinical recommendations at a special medical conference to be held in Tokyo, Japan, on December 16, 2006.
Rexin-G, The World’s First Tumor-Targeted Gene Therapy Vector, Stymies Metastatic Cancer
SAN MARINO, Calif. -- Epeius Biotechnologies recently announced the publication of clinical data from studies conducted at the University of the Philippines, Asian Hospital and Medical Center, Makati Medical Center, Manila, Philippines and Lutheran Medical Center, New York, USA, revealing the safety and single agent efficacy of Rexin-G(TM) for the treatment of a broad spectrum of chemotherapy-resistant cancers.
